Page 3 - கோலின்ஸ் நேரம் ஸ்டாம்பர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

05 February 2020
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. 
The full text announcement is contained below and can be accessed on Achilles website at:
https://achillestx.com/news
.
 
 
Forward-looking statements - this announcement contains certain forward-looking statements with respect to the portfolio of investments of Syncona Limited. These statements and forecasts involve risk and uncertain ....

United Kingdom , City Of , Karl Peggs , Miraj Ali , Collins Tim Stamper , Annabel Clay , Ben Atwell Natalie , Company Clonal Neoantigen Targeting , Safety Monitoring Committee , Syncona Ltd , Ir External Communications , Syncona Limited , Announces Positive Independent Data , Achilles Therapeutics , Independent Data , Natalie Garland Collins , Therapeutics Announces Positive Independent Data , Safety Monitoring Committee Review , Current Study Design , Chief Executive Officer , Chief Medical Officer , Investegate Announcements , Investegate Company Announcements , Regulatory News Service , Regulatory News Service And , ஒன்றுபட்டது கிஂக்டம் ,